VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - May 14, 2007) - Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, reported today in its first quarter operating results that the Company remains on track to achieve all of it’s 2007 milestones, including initiating a third Phase II human clinical trial.
